Administrative Core

路易斯维尔大学肝脏生物学和毒理学COBRE是一个多学科小组， 研究人员专注于肝脏和肝脏损伤，肠道：肝脏相互作用，以及肝脏：环境/毒物/药物 相互作用、酒精性和非酒精性肝损伤、传染性肝脏疾病、肝癌和新肝脏 治疗行政核心的目的是提供行政、财政和科学监督， 第二阶段COBRE。这包括第二阶段的整体职业发展和研究目标 COBRE（包括形成性和总结性评价以及具体的里程碑）;职业发展计划 初级教员（包括向独立过渡的计划）;更换关键人员的计划（例如， 项目PI、核心领导人、总体PI、试点项目PI）;监督试点项目;监督 生物统计支助服务;以及向非专业人员和科学界传播信息。 肝病是一些最常见的，迅速增加和认识不足的健康 困扰美国人的问题例如，非酒精性脂肪性肝病/非酒精性脂肪性肝炎 是美国肝酶异常的最常见原因，影响约25%的成年人和约10%的成年人。 孩子们。酒精性肝病是饮酒者中日益严重的问题。重要的是，没有 FDA批准的NASH或ALD治疗。毒物引起的肝损伤是一种越来越被认识到的 工业/环境问题。病毒性肝病（甲型、B型和丙型肝炎）仍然是主要的健康问题 与吸毒和无家可归有关。肝细胞癌和丙型肝炎是肝硬化的主要原因。 相关的发病率和肝移植在美国。药物性肝损伤是新药研发失败的主要原因 在美国，这是暴发性肝衰竭的主要原因。个性化医疗是 越来越多地被认为是药物治疗的一个重要方面;大多数药物在肝脏中代谢。 在第一阶段COBRE管理核心成功的基础上，第二阶段的具体目标 COBRE管理核心是： 1.继续提供全面的行政、财政和科学监督 2.加强和发展项目PI的职业发展事业 3.加强和发展导师的职业发展/导师发展事业 4.加强和发展COBRE的研究目标 5.继续提供更换关键人员的流程 6.继续为COBRE提供并加强总结性和形成性评估流程， 包括具体的里程碑 7.继续提供强有力的试点项目计划，以实现COBRE的总体研究目标 8.向科学界和外行传播相关信息

The University of Louisville Hepatobiology and Toxicology COBRE is a multidisciplinary group of investigators focusing on the liver and liver injury, gut:liver interactions, and liver:environment/toxicant/drug interactions, alcoholic and non-alcoholic liver injury, infectious liver diseases, liver cancer, and new liver therapies. The purpose of the administrative core is to provide administrative, fiscal and scientific oversight for this Phase II COBRE. This includes the overall career development and research goals of the Phase II COBRE (including formative and summative evaluation and specific milestones); the career development plans for junior faculty (including plans for transitioning to independence); plans for replacing key personnel (e.g., Project PIs, Core leaders, overall PI, pilot project PIs); oversight of the pilot projects; oversight of the biostatistical support services; and disseminating information to the lay and scientific communities. Liver diseases are some of the most common, rapidly increasing and poorly recognized health problems afflicting Americans. For example, Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis is the most common cause of abnormal liver enzymes in the US, affecting about 25% of adults and about 10% of children. Alcoholic Liver Disease is an increasing problem among those who drink. Importantly, there is no FDA-approved therapy for either NASH or ALD. Toxicant-Induced Liver Injury is an increasingly recognized industrial/environmental problem. Viral Liver Diseases (Hepatitis A, B, and C) remain major health problems related to drug abuse and homelessness. Hepatocellular carcinoma and Hepatitis C are major causes for liver related morbidity and liver transplantation in the US. Drug-Induced Liver Injury is the major reason new drugs do not come to market and the major cause of fulminant liver failure in the US. Personalized Medicine is increasingly recognized as an important aspect of drug therapy; and most drugs are metabolized in the liver. Building on the success of the Phase I COBRE Administrative Core, the specific aims of this Phase II COBRE Administrative Core are: 1. continue to provide overall administrative, fiscal and scientific oversight 2. enhance and grow the career development enterprise for project PIs 3. enhance and grow the career development/mentor development enterprise for the mentors 4. enhance and grow the research goals of the COBRE 5. continue to provide a process for replacing key personnel 6. continue to provide and enhance a summative and formative evaluation process for the COBRE, including specific milestones 7. continue to provide a robust pilot project program to grow the overall research goals of the COBRE 8. disseminate pertinent information to the scientific and lay community